Prognostic Factors of Small-Cell Lung Cancer in Okayama Lung Cancer Study Group Trials

Makoto Tamura, Hiroshi Ueoka, Katsuyuki Kiura, Masahiro Tabata, Takuo Shibayama, Kazuyo Miyatake, Kenichi Gemba, Shunkichi Hiraki, Mine Harada

Research output: Contribution to journalArticlepeer-review

19 Citations (Scopus)


In order to elucidate factors influencing the prognosis of small-cell lung cancer (SCLC), we reviewed the records of 253 patients with SCLC and evaluated 20 pretreatment prognostic factors by univariate analysis and Cox's multiple regression analysis. Recursive partitioning and amalgamation (RPA) was employed to identify subgroups with similar survival rates. Cox's multiple regression analysis identified five significant factors: extent of disease, number of metastatic sites, serum albumin, serum lactate dehydrogenase, and presence of weight loss. Among these, extent of disease was the most influential factor. RPA analysis revealed three subgroups predicting significantly different prognoses. The median survival time and 3-year survival rate were 18.4 months and 20.6%, respectively for the good-risk group (limited disease without weight loss), 13.5 months and 9.1 %, respectively for the intermediate-risk group (limited disease with weight loss or extensive disease with less than two metastatic sites), and 9.2 months and 0%, respectively for the poor-risk group (extensive disease with two or more metastatic sites). These results will be useful for development of new staging system or subsequent stratification for randomized trials.

Original languageEnglish
Pages (from-to)105-111
Number of pages7
JournalActa medica Okayama
Issue number2
Publication statusPublished - Apr 1 1998


  • Cox's multiple regression analysis
  • Prognostic factors
  • Recursive partitioning and amalgamation method
  • Small-cell lung cancer

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)


Dive into the research topics of 'Prognostic Factors of Small-Cell Lung Cancer in Okayama Lung Cancer Study Group Trials'. Together they form a unique fingerprint.

Cite this